Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High Risk B-Precursor Acute Lymphoblastic Leukemia.

Trial Profile

High Risk B-Precursor Acute Lymphoblastic Leukemia.

Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Antineoplastics; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Mercaptopurine; Prednisone; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results of risk stratification in childhood B-LL data from two studies including this study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Pooled results of 2 trials including this study and another study [see CTP 700203964] were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top